Canbas Of Japan Gets FDA Orphan Status For Mesothelioma Drug
This article was originally published in PharmAsia News
Executive Summary
Shizuoka based Canbas Co. Ltd Jan. 5 announced it received orphan designation from U.S. FDA for oncology drug candidate CBP501.